The initial success of Sildenafil undeniably transformed the medication landscape, but betting in companies primarily reliant on unbranded versions presents a complex picture. Although early returns were significant, the expiration of patents and the emergence of discounted alternatives have diminished market share. Therefore, a thorough analysis o